Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
Yuina Akagi,
Yusuke Yamashita,
Hideki Kosako,
Yoshiaki Furuya,
Hiroki Hosoi,
Toshiki Mushino,
Shogo Murata,
Akinori Nishikawa,
Shinobu Tamura,
Taisei Nakao,
Takashi Sonoki
Affiliations
Yuina Akagi
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Yusuke Yamashita
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Hideki Kosako
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Yoshiaki Furuya
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Hiroki Hosoi
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Toshiki Mushino
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Shogo Murata
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Akinori Nishikawa
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Shinobu Tamura
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Taisei Nakao
Department of Hematology Naga Municipal Hospital Wakayama Japan
Takashi Sonoki
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
Abstract Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73‐year‐old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.
